Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2026-01-22 Sale | 2026-01-26 4:10 pm | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 5,000 | $45.52 | $227,612 | 21,320 (Direct) | View |
| 2026-01-07 Sale | 2026-01-09 4:51 pm | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 25,156 | $40.2 | $1,011,299 | 312,407 (Direct) | View |
| 2026-01-06 Sale | 2026-01-08 4:30 pm | Maze Therapeutics Inc. | MAZE | Sohn Catherine A. Director | 29,413 | $39.07 | $1,149,054 | 9,332 (Direct) | View |
| 2026-01-02 Sale | 2026-01-06 4:31 pm | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 4,844 | $40.39 | $195,668 | 675,538 (Direct) | View |
| 2026-01-02 Sale | 2026-01-06 4:30 pm | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 5,000 | $39.15 | $195,754 | 18,325 (Direct) | View |
| 2025-12-29 Sale | 2025-12-31 4:24 pm | Maze Therapeutics Inc. | MAZE | Dandekar Atul CSBO | 72,500 | $40.56 | $2,940,799 | 158,889 (Direct) | View |
| 2025-12-29 Sale | 2025-12-31 4:22 pm | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 45,000 | $40.56 | $1,825,355 | 342,407 (Direct) | View |
| 2025-12-29 Sale | 2025-12-31 4:20 pm | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 15,000 | $40.41 | $606,173 | 41,777 (Direct) | View |
| 2025-09-15 Sale | 2025-09-16 4:26 pm | Maze Therapeutics Inc. | MAZE | SCHELLER RICHARD H Director | 20,744 | $22.37 | $464,035 | 0 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2026-01-22 Exercise | 2026-01-26 4:10 pm | N/A 2031-03-03 | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 5,000 | $0 | 21,320 (Direct) | View |
| 2026-01-22 Exercise | 2026-01-26 4:10 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 5,000 | $10.42 | 21,320 (Direct) | View |
| 2026-01-07 Exercise | 2026-01-09 4:51 pm | N/A 2032-10-26 | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 25,156 | $0 | 312,407 (Direct) | View |
| 2026-01-07 Exercise | 2026-01-09 4:51 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 25,156 | $10.42 | 312,407 (Direct) | View |
| 2026-01-06 Exercise | 2026-01-08 4:30 pm | N/A 2033-03-08 | Maze Therapeutics Inc. | MAZE | Sohn Catherine A. Director | 29,413 | $0 | 9,332 (Direct) | View |
| 2026-01-06 Exercise | 2026-01-08 4:30 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Sohn Catherine A. Director | 29,413 | $10.42 | 9,332 (Direct) | View |
| 2026-01-02 Exercise | 2026-01-06 4:31 pm | N/A 2032-10-26 | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 4,844 | $0 | 675,538 (Direct) | View |
| 2026-01-02 Exercise | 2026-01-06 4:31 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 4,844 | $10.42 | 675,538 (Direct) | View |
| 2026-01-02 Exercise | 2026-01-06 4:30 pm | N/A 2032-10-26 | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 5,000 | $0 | 18,325 (Direct) | View |
| 2026-01-02 Exercise | 2026-01-06 4:30 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 5,000 | $10.42 | 18,325 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-31 4:24 pm | N/A 2031-04-11 | Maze Therapeutics Inc. | MAZE | Dandekar Atul CSBO | 72,500 | $0 | 158,889 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-31 4:24 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Dandekar Atul CSBO | 72,500 | $10.42 | 158,889 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-31 4:22 pm | N/A 2032-10-26 | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 45,000 | $0 | 342,407 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-31 4:22 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 45,000 | $10.42 | 342,407 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-31 4:20 pm | N/A 2031-02-01 | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 15,000 | $0 | 41,777 (Direct) | View |
| 2025-12-29 Exercise | 2025-12-31 4:20 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 15,000 | $10.42 | 41,777 (Direct) | View |
| 2025-11-19 Other | 2025-11-21 4:24 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | HOMCY CHARLES J Director | 1,489 | $0 | 40,024 (Direct) | View |
| 2025-11-04 Other | 2025-11-05 4:15 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Third Rock Ventures IV L.P. Third Rock Ventures GP IV L.P. TRV GP IV LLC Third Rock Ventures V L.P. Third Rock Ventures GP V LP TRV GP V LLC 10% Owner | 1,600,000 | $0 | 7,024,758 (Direct) | View |
| 2025-10-23 Gift | 2025-10-27 4:46 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | HOMCY CHARLES J Director | 28,423 | $0 | 37,046 (Direct) | View |
| 2025-10-06 Option Award | 2025-10-07 4:17 pm | N/A 2035-10-05 | Maze Therapeutics Inc. | MAZE | Hoppenot Herve Director | 36,000 | $0 | 36,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:28 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Courtney Phillips GC and Corp. Secretary | 22,000 | $0 | 22,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:26 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Dandekar Atul CSBO | 25,000 | $0 | 25,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:25 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Coloma Jason V Chief Executive Officer | 100,000 | $0 | 100,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:24 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Bernstein Harold President, R&D & CMO | 40,000 | $0 | 40,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:23 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Bachrodt Amy SVP, Finance | 22,000 | $0 | 22,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:21 pm | N/A 2035-09-21 | Maze Therapeutics Inc. | MAZE | SPIEGELMAN DANIEL K Director | 18,000 | $0 | 18,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:19 pm | N/A 2035-09-21 | Maze Therapeutics Inc. | MAZE | Sohn Catherine A. Director | 18,000 | $0 | 18,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:18 pm | N/A 2035-09-21 | Maze Therapeutics Inc. | MAZE | SCHELLER RICHARD H Director | 18,000 | $0 | 18,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:17 pm | N/A 2035-09-21 | Maze Therapeutics Inc. | MAZE | Lim Jonathan E Director | 18,000 | $0 | 18,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:16 pm | N/A 2035-09-21 | Maze Therapeutics Inc. | MAZE | Kathiresan Sekar Director | 18,000 | $0 | 18,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:15 pm | N/A 2035-09-21 | Maze Therapeutics Inc. | MAZE | HOMCY CHARLES J Director | 18,000 | $0 | 18,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:14 pm | N/A 2035-09-21 | Maze Therapeutics Inc. | MAZE | Exter Neil Director | 18,000 | $0 | 18,000 (Direct) | View |
| 2025-09-22 Option Award | 2025-09-24 4:13 pm | N/A 2035-09-21 | Maze Therapeutics Inc. | MAZE | Andrews Nancy C Director | 18,000 | $0 | 18,000 (Direct) | View |
| 2025-09-02 Option Award | 2025-09-02 6:30 pm | N/A 2035-09-01 | Maze Therapeutics Inc. | MAZE | Tahir Misbah Chief Financial Officer | 325,000 | $0 | 325,000 (Direct) | View |
| 2025-08-17 Option Award | 2025-08-19 4:15 pm | N/A 2035-08-16 | Maze Therapeutics Inc. | MAZE | Exter Neil Director | 16,000 | $0 | 16,000 (Direct) | View |
| 2025-02-03 Conversion | 2025-02-04 5:31 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Third Rock Ventures IV L.P. Third Rock Ventures GP IV L.P. TRV GP IV LLC Third Rock Ventures V L.P. Third Rock Ventures GP V LP TRV GP V LLC 10% Owner | 71,439,297 | $0 | 7,024,758 (Direct) | View |
| 2024-12-09 Option Award | 2025-02-04 4:37 pm | N/A 2033-03-08 | Maze Therapeutics Inc. | MAZE | Lim Jonathan E Director | 14,790 | $0 | 343,490 (Direct) | View |
| 2025-02-03 Conversion | 2025-02-04 4:37 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Lim Jonathan E Director | 2,903,040 | $0 | 343,490 (Indirect) | View |
| 2024-12-09 Option Award | 2025-02-04 4:35 pm | N/A 2031-03-03 | Maze Therapeutics Inc. | MAZE | HOMCY CHARLES J Director | 178,402 | $0 | 251,293 (Direct) | View |
| 2025-02-03 Conversion | 2025-02-04 4:35 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | HOMCY CHARLES J Director | 422,206 | $0 | 251,293 (Direct) | View |
| 2024-11-26 Conversion | 2025-02-04 4:35 pm | N/A 2026-12-15 | Maze Therapeutics Inc. | MAZE | HOMCY CHARLES J Director | 75,000 | $78,962 | 251,293 (Indirect) | View |
Ownership | 2025-01-30 8:55 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Third Rock Ventures IV L.P. Third Rock Ventures GP IV L.P. TRV GP IV LLC Third Rock Ventures V L.P. Third Rock Ventures GP V LP TRV GP V LLC 10% Owner | 0 | $0 | 65,036,879 (Direct) | View |
Ownership | 2025-01-30 4:42 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | ARCH Venture Partners X LLC ARCH Venture Partners X L.P. ARCH Venture Partners X Overage L.P. ARCH Venture Fund X L.P. ARCH Venture Fund X Overage L.P. NELSEN ROBERT CRANDELL KEITH Burow Kristina GILLIS STEVEN 10% Owner | 0 | $0 | 37,588,634 (Indirect) | View |
Ownership | 2025-01-30 4:38 pm | N/A 2030-10-25 | Maze Therapeutics Inc. | MAZE | SPIEGELMAN DANIEL K Director | 0 | $0 | 35,534 (Direct) | View |
Ownership | 2025-01-30 4:37 pm | N/A 2031-02-01 | Maze Therapeutics Inc. | MAZE | Sohn Catherine A. Director | 0 | $0 | 35,534 (Direct) | View |
Ownership | 2025-01-30 4:35 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | SCHELLER RICHARD H Director | 0 | $0 | 43,643 (Direct) | View |
Ownership | 2025-01-30 4:34 pm | N/A N/A | Maze Therapeutics Inc. | MAZE | Lim Jonathan E Director | 0 | $0 | 2,630,618 (Direct) | View |